Bimzelx Injection, Solution
Product Images NDC 50474-781

49 FDA label images from Ucb, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 49 technical images submitted to the FDA as part of the official labeling for Bimzelx (NDC 50474-781). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Bimzelx 01)

Figure 1 (Bimzelx 01)
A line graph depicting the IGA response rate over a 56-week period by week for three different bimekizumab treatment regimens. The x-axis represents the week number from 16 to 56, and the y-axis shows the IGA response rate percentage from 0 to 100%. Three lines compare bimekizumab 320 mg every 4 weeks with placebo, and two bimekizumab 320 mg dosing schedules (every 8 weeks and every 4 weeks) as follow-up dosing.*
FDA Label Image

Figure 2 (Bimzelx 02)

Figure 2 (Bimzelx 02)
A line graph depicting PASI90 response rates over 56 weeks for different Bimzelx (bimekizumab) 320 mg dosing regimens. The x-axis represents time in weeks, and the y-axis shows the PASI90 response rate as a percentage. Three lines compare bimekizumab 320 mg every 4 weeks with placebo, every 4 weeks with 320 mg every 8 weeks, and every 4 weeks with 320 mg every 4 weeks, illustrating changes in response rates across the study duration.*
FDA Label Image

Figure 3: Percent Of Subjects Achieving Acr 50 Responses In Trial Psa-1 Through Week 16 (Bimzelx 03)

Figure 3: Percent Of Subjects Achieving Acr 50 Responses In Trial Psa-1 Through Week 16 (Bimzelx 03)
An instructional diagram showing components of a Bimzelx (bimekizumab) injection device. The parts labeled include the cap, needle guard, viewing window, and handle, illustrating the assembly and key features of the subcutaneous injection pen.*
FDA Label Image

Figure 4 (Bimzelx 04)

Figure 4 (Bimzelx 04)
An instructional diagram depicting a prefilled injection device for Bimzelx (bimekizumab). It highlights the viewing window on the barrel and the location of the expiration date on the device.*
FDA Label Image

Figure 5 (Bimzelx 05)

Figure 5 (Bimzelx 05)
An instructional illustration depicting a simplified human figure showing recommended injection sites for Bimzelx (bimekizumab) subcutaneous injection. The highlighted areas indicate the abdomen or thigh as injection locations. The caption below reads 'Abdomen or thigh Figure C.'*
FDA Label Image

Figure 6 (Bimzelx 06a)

Figure 6 (Bimzelx 06a)
A line graph showing responder rates (%) over a 16-week period for Bimzelx (bimekizumab) 320 mg administered every two weeks (Q2W) compared to placebo in two different study groups (HS0003 and HS0004). The graph includes data points at weeks 0, 2, 4, 8, 12, and 16 with separate lines for placebo and Bimzelx groups, illustrating higher responder rates in the Bimzelx groups across the study duration.*
FDA Label Image

Figure A (Bimzelx 06)

Figure A (Bimzelx 06)
An instructional diagram illustrating the proper injection site for a subcutaneous injection of Bimzelx. The image shows the back of a person's arm, indicating where the injection should be administered.*
FDA Label Image

Figure B (Bimzelx 07)

Figure B (Bimzelx 07)
An instructional illustration showing a person holding a prefilled injection device with both hands, positioned for subcutaneous administration. The left hand holds the device near the dose window, and the right hand grips the opposite end, indicating preparation or use of the injection device.*
FDA Label Image

Figure C (Bimzelx 08)

Figure C (Bimzelx 08)
An instructional illustration labeled Figure F showing a hand holding a syringe or injection device at a 90-degree angle to the injection site, demonstrating the proper technique for subcutaneous injection.*
FDA Label Image

Figure D (Bimzelx 09)

Figure D (Bimzelx 09)
An instructional illustration showing a hand holding an injection pen with an arrow pointing downward, indicating the first click sound when pressing the pen tip to the skin for subcutaneous injection.*
FDA Label Image

Figure E (Bimzelx 10)

Figure E (Bimzelx 10)
An instructional illustration labeled Figure H showing a hand holding an injector device vertically with a yellow internal indicator. A 15-second timer is displayed in the upper right corner, and the text "2nd Click" indicates an action to be performed during injection.*
FDA Label Image

Figure F (Bimzelx 11)

Figure F (Bimzelx 11)
An instructional illustration showing a hand holding a prefilled syringe solution, positioned above the opening of an automated injection device, labeled as Figure 1.*
FDA Label Image

Figure G (Bimzelx 12)

Figure G (Bimzelx 12)
An instructional diagram illustrating the parts of a prefilled syringe for Bimzelx (bimekizumab) injection, solution. Labeled components include the needle cap, needle, syringe barrel, finger grip, plunger rod, and plunger head.*
FDA Label Image

Figure H (Bimzelx 13)

Figure H (Bimzelx 13)
An instructional illustration showing a pre-filled syringe labeled 'EXP' indicating the location of the expiration date on the syringe barrel. The syringe is intended for subcutaneous injection, with a plunger and needle cap depicted in blue and gray colors.*
FDA Label Image

Figure I (Bimzelx 14)

Figure I (Bimzelx 14)
An instructional illustration showing the recommended subcutaneous injection sites for the medication Bimzelx (bimekizumab). The image highlights the abdomen and thighs as suitable areas for injection administration, labeled as Figure C.*
FDA Label Image

Figure A (Bimzelx 15)

Figure A (Bimzelx 15)
An instructional diagram showing the back of a person's arm, indicating the injection site for subcutaneous administration. The figure is labeled 'Back of arm' and illustrates the recommended injection location for Bimzelx (bimekizumab) injection solution.*
FDA Label Image

Figure B (Bimzelx 16)

Figure B (Bimzelx 16)
An instructional illustration labeled Figure E showing two hands preparing an injection. One hand holds a syringe with a needle, while the other hand is removing a protective cap from the needle in preparation for subcutaneous injection.*
FDA Label Image

Figure C (Bimzelx 17)

Figure C (Bimzelx 17)
An instructional illustration showing how to inject the Bimzelx subcutaneous injection at a 45-degree angle into the abdomen. The image depicts a person holding the syringe and injecting the medication into the skin.*
FDA Label Image

Figure D (Bimzelx 18)

Figure D (Bimzelx 18)
An instructional illustration showing a hand holding a syringe for subcutaneous injection. The syringe is positioned to inject into the skin, with an arrow indicating the direction of needle insertion.*
FDA Label Image

Figure E (Bimzelx 19)

Figure E (Bimzelx 19)
An instructional illustration showing a hand holding a syringe for subcutaneous injection. The syringe is inserted at an angle into the skin, with a check mark indicating correct injection technique.*
FDA Label Image

Figure F (Bimzelx 20)

Figure F (Bimzelx 20)
An instructional illustration showing the use of a pre-filled syringe for subcutaneous injection. It depicts a hand holding the syringe while the other hand is positioned to receive the injection, indicating the injection technique for a medication like Bimzelx (bimekizumab) injection.*
FDA Label Image

Figure G (Bimzelx 21)

Figure G (Bimzelx 21)
An instructional illustration showing a hand holding a syringe labeled Bimzelx, preparing to inject the solution into a device or container with a circular opening, possibly for disposal or further handling of the injection material.*
FDA Label Image

Figure H (Bimzelx 22)

Figure H (Bimzelx 22)
Bimzelx (bimekizumab-bkzx) Injection 160 mg/mL per autoinjector subcutaneous injection label. The packaging contains two single-dose autoinjectors, each delivering 160 mg in 1 mL. The label includes preparation and injection instructions, storage conditions, and manufacturer details (UCB, Inc.). The product is labeled for prescription use only.*
FDA Label Image

Figure I (Bimzelx 23)

Figure I (Bimzelx 23)
Bimzelx (bimekizumab-bkzx) Injection 160 mg/mL prefilled syringes packaging label for subcutaneous injection. The label states two single-dose prefilled syringes each delivering 160 mg in 1 mL are included. The labeler is UCB, Inc. It includes storage instructions to refrigerate between 2 to 8°C and warnings not to freeze or shake. A quick start guide with syringe preparation and injection steps is illustrated on the label.*
FDA Label Image

Figure J (Bimzelx 24)

Figure J (Bimzelx 24)
An instructional illustration showing a hand holding a syringe to inject a solution into a disposal container with a lid, indicating proper disposal of injection materials for Bimzelx (bimekizumab) subcutaneous injection solution.*
FDA Label Image

Figure A (Bimzelx 25)

Figure A (Bimzelx 25)
Illustration diagram showing the components of a Bimzelx injection pen including the cap, viewing window, needle guard (with needle inside), and handle, providing a labeled overview of the subcutaneous injection device parts.*
FDA Label Image

Figure B (Bimzelx 26)

Figure B (Bimzelx 26)
An instructional illustration showing a prefilled injection pen for Bimzelx (bimekizumab) subcutaneous injection. The image highlights the viewing window on the device, used to observe the solution, and the location of the expiration date on the pen.*
FDA Label Image

Figure C (Bimzelx 27)

Figure C (Bimzelx 27)
An instructional illustration labeled 'Figure C' showing recommended injection sites for a subcutaneous injection. The image depicts a simplified human torso with highlighted areas on the abdomen and thighs as preferred sites for injection.*
FDA Label Image

Figure D (Bimzelx 28)

Figure D (Bimzelx 28)
An instructional illustration showing the back of the arm as an injection site area for subcutaneous administration. The shaded area on the back of the upper arm indicates where the injection should be given.*
FDA Label Image

Figure E (Bimzelx 29)

Figure E (Bimzelx 29)
An instructional illustration labeled 'Figure E' showing hands removing a cap from a pen-style injection device by pulling it off to the left. This likely demonstrates part of the preparation process for a subcutaneous injection of Bimzelx (bimekizumab).*
FDA Label Image

Figure F (Bimzelx 30)

Figure F (Bimzelx 30)
An instructional illustration depicting a hand holding a Bimzelx injection pen at a 90-degree angle, demonstrating the proper positioning for subcutaneous injection.*
FDA Label Image

Figure G (Bimzelx 31)

Figure G (Bimzelx 31)
An instructional illustration labeled Figure G showing a hand holding a pre-filled pen or syringe. The image indicates pressing down until a '1st Click' sound is heard, suggesting a step in the activation or injection process for Bimzelx (bimekizumab) subcutaneous injection.*
FDA Label Image

Figure H (Bimzelx 32)

Figure H (Bimzelx 32)
An instructional diagram labeled "Figure H" showing a hand holding a syringe-like device with a highlighted "2nd Click" indication. The image features arrows on both sides pointing outward with the word "HOLD" beneath each arrow, likely indicating a step in the medication administration process.*
FDA Label Image

Figure I (Bimzelx 33)

Figure I (Bimzelx 33)
An instructional illustration showing a hand holding a prefilled syringe with the needle pointing downward. The image includes a timer icon and text indicating to slowly count to 5 before proceeding, suggesting a pause or wait after injection.*
FDA Label Image

Figures J (Bimzelx 34)

Figures J (Bimzelx 34)
An instructional illustration showing a hand holding a prefilled syringe as it is being inserted into an injection port or device. The image appears to demonstrate how to connect or prepare the subcutaneous injection device for administration.*
FDA Label Image

Figure A (Bimzelx 35)

Figure A (Bimzelx 35)
An instructional diagram labeled Figure A depicting parts of a syringe used for injection, including the needle cap, needle, syringe barrel, finger grip, plunger rod, and plunger head.*
FDA Label Image

Figure B (Bimzelx 36)

Figure B (Bimzelx 36)
An instructional diagram showing a syringe with a viewing window that reveals the expiration date on the drug cartridge. The expiration date is located on the cartridge, labeled 'EXP.' The diagram highlights the viewing window and expiration date for the user to check before administration.*
FDA Label Image

Figure C (Bimzelx 37)

Figure C (Bimzelx 37)
An instructional illustration labeled Figure C shows areas on the human body suitable for subcutaneous injection of Bimzelx (bimekizumab). Highlighted regions include the abdomen and the front of the thighs, indicating these as injection sites for the medication.*
FDA Label Image

Figure D (Bimzelx 38)

Figure D (Bimzelx 38)
An instructional illustration labeled 'Figure D' showing the back of the upper arm area as a site for subcutaneous injection administration.*
FDA Label Image

Figure E (Bimzelx 39)

Figure E (Bimzelx 39)
An instructional illustration showing a person removing the cap from a syringe before injection. The image depicts two hands, one holding the syringe and the other pulling off the needle cap, with an arrow indicating the direction to remove the cap. This figure is likely part of subcutaneous injection preparation instructions.*
FDA Label Image

Figure F (Bimzelx 40)

Figure F (Bimzelx 40)
An instructional illustration demonstrating the subcutaneous injection technique for Bimzelx (bimekizumab). It shows a person inserting the injection needle at a 45-degree angle into the skin of the abdomen, with guidance to lift the skin for proper injection.*
FDA Label Image

Figure G (Bimzelx 41)

Figure G (Bimzelx 41)
An instructional illustration showing a hand administering a subcutaneous injection using a prefilled syringe. The image highlights the proper thumb placement to press the plunger of the syringe into the injection site, consistent with instructions for administering Bimzelx (bimekizumab) injection.*
FDA Label Image

Figure H (Bimzelx 42)

Figure H (Bimzelx 42)
An instructional illustration showing a hand administering a subcutaneous injection using a syringe or auto-injector device into the skin, marked with a check mark indicating the correct technique. This relates to the injection method for Bimzelx (bimekizumab) subcutaneous solution.*
FDA Label Image

Figure I (Bimzelx 43)

Figure I (Bimzelx 43)
An instructional illustration showing a person using a syringe-like device to administer an injection subcutaneously in the arm. The image highlights removing the cap from the injection device, indicated by an arrow pointing outward from the cap.*
FDA Label Image

Figure J (Bimzelx 44)

Figure J (Bimzelx 44)
An instructional illustration showing a hand holding a syringe above a sharps container, demonstrating the proper disposal of the syringe by inserting it into the container's designated opening. This guidance is related to the safe disposal of injection equipment.*
FDA Label Image

Principal Display Panel (160 mg/mL Autoinjector Carton)

Principal Display Panel (160 mg/mL Autoinjector Carton)
Bimzelx (bimekizumab-bkzx) Injection 160 mg/mL per autoinjector is a subcutaneous injection presented in a package containing two single-dose autoinjectors. The label instructs that each autoinjector delivers 160 mg in 1 mL of bimekizumab-bkzx, and two autoinjectors are required for a 320 mg dose. Labeler is UCB, Inc.*
FDA Label Image

Principal Display Panel (160 mg/mL Syringe Carton)

Principal Display Panel (160 mg/mL Syringe Carton)
Bimzelx (bimekizumab-bkzx) Injection 160 mg/mL prefilled syringes carton label. The package contains two single-dose syringes, each delivering 160 mg in 1 mL for subcutaneous use only. The label includes storage instructions, a composition list per syringe, manufacturer information (UCB, Inc.), and step-by-step injection instructions with illustrations. It states that two syringes are required for a 320 mg dose and includes a Quick Start Guide section.*
FDA Label Image

Principal Display Panel (320 mg/2 mL autoinjector Carton)

Principal Display Panel (320 mg/2 mL autoinjector Carton)
Packaging label for Bimzelx (bimekizumab-bkzx) Injection, 320 mg/2 mL autoinjector, a subcutaneous injection solution. The label includes product information, dosage strength, and storage instructions. The labeler is UCB, Inc. It also features a graphic of the autoinjector device and a quick start guide outlining injection steps and precautions.*
FDA Label Image

Principal Display Panel (320 mg/2 mL Syringe Carton)

Principal Display Panel (320 mg/2 mL Syringe Carton)
Packaging label for Bimzelx (bimekizumab-bkzx) Injection, a subcutaneous injection solution. The label highlights a 320 mg/2 mL (160 mg/mL) prefilled syringe, with directions to dispense the enclosed medication guide. Manufacturer is UCB, Inc. The carton provides storage instructions, ingredient details, and a quick start guide for injection preparation and administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.